/
Combining estrogen receptor blockade and radiation therapy to improve the response of Combining estrogen receptor blockade and radiation therapy to improve the response of

Combining estrogen receptor blockade and radiation therapy to improve the response of - PowerPoint Presentation

MommaBear
MommaBear . @MommaBear
Follow
342 views
Uploaded On 2022-08-02

Combining estrogen receptor blockade and radiation therapy to improve the response of - PPT Presentation

Zachary Morris MDPhD Assistant Prof Dept of Human Oncology September 11 2019 gt70 of breast cancers are ER Growth of 2540 is resistant to antiestrogens Metastatic ER cancers account for most breast ID: 932644

radiation immune breast tumor immune radiation tumor breast cells anti cancer response estrogen nm600 cancers inhibition sites checkpoint overcome

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Combining estrogen receptor blockade and..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Combining estrogen receptor blockade and radiation therapy to improve the response of breast cancer to immunotherapies

Zachary Morris, MD/PhDAssistant Prof. Dept of Human Oncology

September 11, 2019

Slide2

>70% of breast cancers are

ER

+Growth of 25-40% is resistant to anti-estrogens

Metastatic ER+ cancers account for most breast

cancer

mortality

Breast Cancers

ER+

Anti-E

Resistant

The Challenge of Metastatic ER+ Breast Cancer

Slide3

ER+ breast cancer is typically immunologically “cold”

Few mutations =

few antigensFew tumor infiltrating lymphocytesLower response to immune checkpoint inhibitors

Slide4

Radiation may overcome mechanisms of tumor immune escape

Radiation

Immunogenic cell

death

Changes

in cells surviving radiation

Inflammation

Seconds

Hours

Days

Weeks

Temporary local depletion of

suppressor immune cells

Increased immune infiltrate

Immune recognition of tumor antigens not recognized prior to radiation

Slide5

Slide6

Radiation may increase tumor infiltration by and activation of immune suppressive myeloid cells

Anti-tumor Response

No anti-tumor ResponseJeong et al., Blood Res, 2016

Slide7

Estrogen

and anti-estrogens modulate recruitment and activation of suppressive immune cells in tumors

Need immunocompetent model of ER+ breast cancer

Slide8

NRL-PRL transgenic

model produces

spontaneous, metastatic ER+ cancers in mice

H&E

ER

α

PgR

Allows testing of estrogen and immune interactions

Bone

Lung

ER

α

Anti-estrogens fail

to inhibit

growth

Estrogen activity modulates gene expression

Few mutations

Few CD8

+ lymphocytic

infiltrate but

higher numbers of F4/80+ immune

cells

Slide9

Combined radiation and estrogen inhibition modify tumor cell immune susceptibility

Slide10

Dose-dependent activation of viral response pathways in tumor cells surviving radiation

Suppressive cells (MDSC)

Antigen presenting helper cells (DCs)Ratio of effector : suppressor T cells

Slide11

Radiation + estrogen inhibition increases response to anti-PD-1 immune checkpoint blockade

Slide12

Approaches to better propagate the

anti-tumor immune response to radiation + ER inhibition + anti-PD-1 in breast cancer - Deliver radiation to all tumor sites

- Overcome additional mechanisms of tumor immune suppression

Slide13

NM600,

a MTRT agent, is capable of safely delivering

radiation to all sites of disease in various murine and human cancers Yttrium-90; molecular radiotherapeuticYttrium-86; PET imaging

NM600 – Alkylphosphocholine

with specific uptake in B78

melanoma and most tumors

86Y-NM600

Free 86

YMelanoma (B78)86Y-NM600 PET/CT

TC11 Breast Cancer

Slide14

NM600 can deliver low dose radiation to all tumor sites in breast cancer models and improve response to immune checkpoint blockade

Slide15

Approaches to better propagate the

anti-tumor immune response to radiation + ER inhibition + anti-PD-1 in breast cancer - Deliver radiation to all tumor sites

- Overcome additional mechanisms of tumor immune suppression

Slide16

CD73 expression may reduce the immunogenic effects of radiotherapy

S. de

Leve et al., Front Immunol, 2019

Slide17

CD73 is highly expressed on murine breast cancer cells and is associated with poor prognosis in ER+ breast cancer patients

Slide18

Experimental

Design

ER+

TC11 cells

Initiate

treatment when tumors

150 mm

3

:

8 Gy x1 (d1)Fulvestrant, 5 mg weekly (d-6, 1, 8)MEDI9447 anti-CD73, 12.5 mg/kg IP (d3)ER-

4T1

cells

Slide19

Acknowledgements

Morris LabRaghava SriramaneniRavi PatelWonjong JinAmber Bates

Paul ClarkBen LanJustin JagodinskyElizabeth SumiecSarah EmmaErin NystuenClaire BanielPeter CarlsonFundingUWCCC CITI Pilot AwardSupportAstraZeneca - MedImmuneSchuler LabKathy O’Leary